Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vudalimab - Xencor

Next Previous
Search
Drug Profile

Vudalimab - Xencor

Alternative Names: PD-1 x CTLA-4 - Xencor; XmAb 717; XmAb-20717

Latest Information Update: 12 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xencor
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Biliary cancer; Gynaecological cancer; Non-small cell lung cancer; Prostate cancer; Urogenital cancer

Most Recent Events

  • 27 Feb 2025 Suspended - Phase-I for Prostate cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
  • 27 Feb 2025 Suspended - Phase-I/II for Non-small cell lung cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (IV)
  • 27 Feb 2025 Suspended - Phase-II for Biliary cancer (Late-stage disease, Second-line therapy or greater) in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top